UK markets closed
  • NIKKEI 225

    28,860.62
    +405.02 (+1.42%)
     
  • HANG SENG

    23,996.87
    +13.21 (+0.06%)
     
  • CRUDE OIL

    72.60
    +0.55 (+0.76%)
     
  • GOLD FUTURES

    1,785.10
    +0.40 (+0.02%)
     
  • DOW

    35,754.75
    +35.32 (+0.10%)
     
  • BTC-GBP

    38,403.81
    -179.58 (-0.47%)
     
  • CMC Crypto 200

    1,323.69
    +18.57 (+1.42%)
     
  • ^IXIC

    15,786.99
    +100.07 (+0.64%)
     
  • ^FTAS

    4,177.65
    -1.11 (-0.03%)
     

Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board

·5-min read

DGAP-News: Mainz BioMed N.V. / Key word(s): Personnel/Strategic Company Decision
18.11.2021 / 09:01
The issuer is solely responsible for the content of this announcement.

- Former Danaher executive provides significant clinical, global market, and product development expertise in cancer diagnostics


BERKELEY, CA - MAINZ, Germany - NOVEMBER 18, 2021 -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Soren Thestrup-Nielsen M.D. to its Strategic Advisory Board.

"It's a pleasure to welcome Soren to our newly formed Strategic Advisory Board as he brings us tremendous leadership in all aspects of a product's life cycle," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "All of us at the company are excited to work with Soren as we embark on ColoAlert's commercial roll-out across Europe and develop the regulatory and clinical strategy for the U.S. market."

Dr. Thestrup-Nielsen has spent over 25 years in the medical device industry, first at Boston Scientific and later at Danaher Corporation where he led the inorganic growth of Danaher's acute care and laboratory diagnostics portfolio. He has previously held a series of notable executive roles including Chairman of Althea Group, as well as board member at numerous companies including lung cancer screening company Oncimmune. During his career Dr. Thestrup-Nielson has overseen IPO's, trade-sales, acquisitions, and a variety of investment transactions with medical companies in both North America and Europe. He received a M.D. from the University of Copenhagen, School of Medicine, practiced 5 years as a general & vascular surgeon, and received an MBA from the IMD in Lausanne, Switzerland.

In his advisory role with Mainz Biomed, Dr. Thestrup-Nielsen will take an active role in the development of the Company product strategy for Europe, the United States, and the rest of the world, to include clinical development, market segmentation, go-to-market strategy, and regulatory strategy. He will also provide expert counsel on the development of the global commercial strategy, the development of the clinical strategy for future iterations of Mainz Biomed's ColoAlert test and lead the clinical advisors board once established.

About Mainz Biomed N.V.

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe. In the USA, Mainz Biomed will begin the clinical study and regulatory process in the first half of 2022 for U.S. FDA approval. Mainz Biomed's product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

For more information please visit www.mainzbiomed.com

For media enquiries, please contact press@mainzbiomed.com

For investor enquiries, please contact ir@mainzbiomed.com

Forward Looking Statements

Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.


18.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Mainz BioMed N.V.

Robert-Koch-Strasse 50

55129 Mainz

Germany

Internet:

mainzbiomed.com

EQS News ID:

1250051


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting